Magenta's R&D head hits the exit just weeks after reading out mid-stage data for lead therapy, eyeing clinic for another

Cambridge, MA-based Magenta Therapeutics has had a mostly quiet few years as it steers its stem cell transplant hopefuls through early-stage human trials. For the past three years, that early clinical work was headed up by Pfizer veteran John Davis — but now, Davis is taking off right as the biotech’s lead drug preps for a late-stage test.